表紙:癌治療用生物製剤の世界市場:2019年~2023年
市場調査レポート
商品コード
832988

癌治療用生物製剤の世界市場:2019年~2023年

Global Cancer Biologics Market 2019-2023

出版日: | 発行: TechNavio (Infiniti Research Ltd.) | ページ情報: 英文 127 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.84円
癌治療用生物製剤の世界市場:2019年~2023年
出版日: 2019年04月17日
発行: TechNavio (Infiniti Research Ltd.)
ページ情報: 英文 127 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

癌の世界的な発生率の上昇は、予測期間中の市場成長に影響を与える見通しです。タバコの喫煙や汚染、食習慣の変化など、環境要因の増殖が、世界的な癌の発生率の増加に直接寄与すると予想されます。このような状況のこのような発生率の上昇が、予測期間中の癌治療用生物製剤市場の成長を後押しすることになるでしょう。 Technavioのアナリストは、世界の癌治療用生物製剤市場が2023年までに11%以上のCAGRで成長すると予測しています。

当レポートでは、世界の癌治療用生物製剤市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

第1章 エグゼクティブサマリー

第2章 レポートの範囲

  • イントロダクション1
  • イントロダクション2
  • 米ドルの通貨換算レート

第3章 市場状況

  • 市場のエコシステム
  • 市場の特徴
  • 市場セグメンテーション分析

第4章 市場規模

  • 市場の定義
  • 市場規模(2018年)
  • 市場規模および予測(2018年~2023年)

第5章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • 競争相手の脅威
  • 市況

第6章 市場セグメンテーション:製品別

  • 市場セグメンテーション:製品別
  • 製品別比較:市場規模および予測(2018年~2023年)
  • モノクローナル抗体
  • ワクチン
  • 細胞/遺伝子治療
  • その他
  • 市場機会:製品別

第7章 顧客情勢

第8章 地域情勢

  • 地域別セグメンテーション
  • 地域別比較:市場規模および予測(2018年~2023年)
  • 北米
  • 欧州
  • アジア
  • その他の地域
  • 主要国
  • 市場機会

第9章 意思決定の枠組み

第10章 成長要因と課題

  • 市場成長要因
  • 市場の課題

第11章 市場動向

第12章 ベンダー情勢

  • 概要
  • 創造的破壊の状況

第13章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.

第14章 付録

  • 調査方法
  • 略語のリスト

第15章 TECHNAVIOについて

目次
Product Code: IRTNTR31171

About this market

The rising global incidences of cancer are likely to impact the market's growth during the forecast period. Increasing prevalence of environmental factors including tobacco smoking and pollution and changing dietary patterns are expected to contribute directly to the increased global incidences of cancer. Such rising incidences of this condition will eventually contribute to the cancer biologics market growth during the forecast period. Technavio's analysts have predicted that the cancer biologics market will register a CAGR of over 11% by 2023.

Market Overview

The rising global incidence of cancer

The major etiological factors leading to cancer include genetic mutations, environmental factors such as tobacco smoking and pollution, and changing dietary patterns. The rising prevalence of these factors has directly contributed to the increased global incidence of cancer.

Patient expiry of major cancer biologics

The emergence of biosimilars due to patent expiration of biologics hinder the market growth, despite the increased incidence of cancer during the forecast period.

For the detailed list of factors that will drive and challenge the growth of the cancer biologics market during 2019-2023, view our report.

Competitive Landscape

The market appears to be highly concentrated with the presence of a few market players. Manufacturers in the global cancer biologics market are entering into strategic collaborations to develop or commercialize biologics indicated for the treatment of various types of cancer. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Monoclonal antibodies - Market size and forecast 2018-2023
  • Vaccines - Market size and forecast 2018-2023
  • Cell and gene therapy - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations

PART 15: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global oncology therapeutics market
  • Exhibit 02: Segments of global oncology therapeutics market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Product - Market share 2018-2023 (%)
  • Exhibit 18: Comparison by product
  • Exhibit 19: Monoclonal antibodies - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 20: Monoclonal antibodies - Year-over-year growth 2019-2023 (%)
  • Exhibit 21: Vaccines - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Vaccines - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Cell and gene therapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Cell and gene therapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Others - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 26: Others - Year-over-year growth 2019-2023 (%)
  • Exhibit 27: Market opportunity by product
  • Exhibit 28: Customer landscape
  • Exhibit 29: Market share by geography 2018-2023 (%)
  • Exhibit 30: Geographic comparison
  • Exhibit 31: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 39: Key leading countries
  • Exhibit 40: Market opportunity
  • Exhibit 41: Biologics in the pipeline for cancer
  • Exhibit 42: List of recently approved cancer biologics by the FDA
  • Exhibit 43: Cancer biologics and their biosimilar versions
  • Exhibit 44: Impact of drivers and challenges
  • Exhibit 45: List of collaborations between manufacturers of cancer biologics
  • Exhibit 46: List of predictive biomarkers for cancer
  • Exhibit 47: Vendor landscape
  • Exhibit 48: Landscape disruption
  • Exhibit 49: Vendors covered
  • Exhibit 50: Vendor classification
  • Exhibit 51: Market positioning of vendors
  • Exhibit 52: Amgen Inc. - Vendor overview
  • Exhibit 53: Amgen Inc. - Business segments
  • Exhibit 54: Amgen Inc. - Organizational developments
  • Exhibit 55: Amgen Inc. - Geographic focus
  • Exhibit 56: Amgen Inc. - Key offerings
  • Exhibit 57: Bristol-Myers Squibb Company - Vendor overview
  • Exhibit 58: Bristol-Myers Squibb Company - Business segments
  • Exhibit 59: Bristol-Myers Squibb Company - Organizational developments
  • Exhibit 60: Bristol-Myers Squibb Company - Geographic focus
  • Exhibit 61: Bristol-Myers Squibb Company - Key offerings
  • Exhibit 62: Eli Lilly and Company - Vendor overview
  • Exhibit 63: Eli Lilly and Company - Business segments
  • Exhibit 64: Eli Lilly and Company - Organizational developments
  • Exhibit 65: Eli Lilly and Company - Geographic focus
  • Exhibit 66: Eli Lilly and Company - Segment focus
  • Exhibit 67: Eli Lilly and Company - Key offerings
  • Exhibit 68: F. Hoffmann-La Roche Ltd - Vendor overview
  • Exhibit 69: F. Hoffmann-La Roche Ltd - Business segments
  • Exhibit 70: F. Hoffmann-La Roche Ltd - Organizational developments
  • Exhibit 71: F. Hoffmann-La Roche Ltd - Geographic focus
  • Exhibit 72: F. Hoffmann-La Roche Ltd - Segment focus
  • Exhibit 73: F. Hoffmann-La Roche Ltd - Key offerings
  • Exhibit 74: Merck & Co., Inc. - Vendor overview
  • Exhibit 75: Merck & Co., Inc. - Business segments
  • Exhibit 76: Merck & Co., Inc. - Organizational developments
  • Exhibit 77: Merck & Co., Inc. - Geographic focus
  • Exhibit 78: Merck & Co., Inc. - Segment focus
  • Exhibit 79: Merck & Co., Inc. - Key offerings
  • Exhibit 80: Validation techniques employed for market sizing